{
  "id": 17236452,
  "title": "Up 55% in October: Is Bausch Health’s turnaround just getting started?",
  "url": "https://urgent.news/2026/10/30/up-55-in-october-is-bausch-healths-turnaround-just-getting-started",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T14:32:33.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/up-55-in-october-is-bausch-healths-turnaround-just-getting-started-4988066"
  },
  "original_language": "en",
  "account": "Bausch Health Companies Inc (NYSE:BHC) stock experienced a remarkable surge of 55.50% in a single month, catching many investors off guard. Known for its heavy debt burden and legacy issues, the pharmaceutical manufacturer had been a Wall Street stock to avoid for years. However, under the guidance of CEO Thomas Appio, Bausch Health displayed a compelling turnaround, garnering attention from InvestingPro's models early on.\n\nOver the past 13 quarters, the company has consistently shown growth, with year-over-year revenue and adjusted EBITDA growth across its core business. The latest quarter saw a significant boost, with consolidated revenue reaching $2.85 billion, up 13% year-over-year and beating analyst expectations by 7.1%. Adjusted EBITDA also jumped 28% to $1.075 billion, surpassing Wall Street consensus by 22.3%, leading management to raise full-year 2026 guidance.\n\nSeveral core divisions played a crucial role in this acceleration. Bausch Health's gastrointestinal business, Salix, reported a 21% year-over-year revenue increase to $758 million, driven by the strong performance of its flagship therapy Xifaxan, which surged 26%. The company's medical aesthetics unit, Solta Medical, expanded 38% year-over-year, fueled by its Shibo integration in China that established a $330 million annualized segment profit run rate.\n\nThe surge in margins and expanding cash flow have enabled the company to pay down a substantial amount of debt, bringing net debt to $13.7 billion. Bausch Health's valuation remains attractive, trading at a forward price-to-earnings multiple of just 1.38x and an enterprise value of 5.45 times EBITDA. With a low beta of 0.37, the stock is virtually uncorrelated with market swings, making it an appealing option for investors focused on operational execution and cash flow generation.\n\nDespite the impressive turnaround, Bausch Health still faces risks such as total debt of $20.8 billion and the management of long-term patent expirations. However, its strong gross profit margins of 71.8% and rapidly expanding cash flow provide a substantial cushion, setting it apart from more speculative healthcare investments.\n\nBausch Health's remarkable performance aligns with a broader trend, where healthcare has become Wall Street's top-performing sector over the past six months. As investors rotate towards recession-resistant cash flows due to elevated interest rates and declining tech valuations, Bausch Health presents a high-conviction opportunity with a forward Fair Value of $9.90 per share, signaling an additional 55.8% upside from its current trading price of $6.35.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}